Marianne Mancini serves as the Chief Operating Officer at Viking Therapeutics Inc., a position she has held with distinction. With a robust background in the biopharmaceutical industry, Mancini has been instrumental in steering Viking Therapeutics towards its goal of developing innovative therapies for metabolic and endocrine disorders. Before joining Viking Therapeutics, she held various leadership roles at other biopharmaceutical companies, where she honed her skills in operations, strategic planning, and product development. At Viking Therapeutics, Mancini's role encompasses overseeing the company's operational strategies and ensuring that the organization's day-to-day activities align with its long-term objectives. Her leadership has been pivotal in advancing the company's clinical programs, including the development of novel treatments for obesity and non-alcoholic steatohepatitis (NASH). Under her guidance, Viking Therapeutics has made significant strides in its research and development efforts, positioning the company as a key player in the biopharmaceutical sector. Mancini's achievements extend beyond her operational role; she is also recognized for her contributions to the industry through her participation in various professional organizations and conferences. Her strategic vision and commitment to excellence have earned her a reputation as a respected leader in the field. As Viking Therapeutics continues to grow and evolve, Mancini's expertise and leadership will undoubtedly play a crucial role in shaping the company's future successes.